news
$Conduit Pharmaceuticals (CDT.US)$ Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
39 SECONDS AGO, 8:30 AM EDT
VIA GLOBENEWSWIRE
• Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals", "Conduit" or the "Company") today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases. This approval follows recent grants in the U.S., Japan and Australia and further strengthens Conduit's global intellectual property position as it advances out-licensing discussions. Notably, South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, making this an important strategic milestone in expanding Conduit's reach across a highly valuable Asia-Pacific pharmaceutical region.
"The approval from the Korean Intellectual Property Office represents another key milestone in our IP strategy," said Dr. Andrew Regan, Chief Executive Officer of Conduit Pharmaceuticals. "With growing international patent coverage for AZD1656, we are continuing to build a strong foundation for global partnerships and long-term value creation."
39 SECONDS AGO, 8:30 AM EDT
VIA GLOBENEWSWIRE
• Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals", "Conduit" or the "Company") today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases. This approval follows recent grants in the U.S., Japan and Australia and further strengthens Conduit's global intellectual property position as it advances out-licensing discussions. Notably, South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, making this an important strategic milestone in expanding Conduit's reach across a highly valuable Asia-Pacific pharmaceutical region.
"The approval from the Korean Intellectual Property Office represents another key milestone in our IP strategy," said Dr. Andrew Regan, Chief Executive Officer of Conduit Pharmaceuticals. "With growing international patent coverage for AZD1656, we are continuing to build a strong foundation for global partnerships and long-term value creation."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Popular Gold Mining Stocks Popular Gold Mining Stocks
Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave. Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave.
Unlock Now
